ICML 2019 | DIAL me in: dual immunodulation in aggressive lymphoma

Jose Villasboas

Jose Villasboas, MD, Mayo Clinic, Rochester, Minnesota, MN, discusses the rationale and design of the ongoing Phase II Dual Immunomodulation in Aggressive Lymphoma (DIAL) trial (NCT03038672). This trial investigates varilumab plus nivolumab in aggressive B-cell lymphomas. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  
Similar topics